Danish “bioconvergence” company stock craters 84% since August; Nektar sours on layoffs; Caladrius steady on Cend merger; Eliem slips after clinical setbacks; Molecular Partners falls on Amgen, Novartis news
BICO, which has seen its stock plunge 84% since its 52-week high in August 2021, commercialized the first bio-based ink in 2016 but has since moved far beyond bioprinting and on-demand biofabrication of human organs and tissues. BICO has undertaken a buying spree in recent years that has grown the company into a family of 14 companies—most recently completing the purchase of Biosero, a San Diego developer of software solutions and services designed to enable seamless laboratory automation. [BICO Group]
BICO commercialized the first bio-based ink in 2016 but has since moved far beyond bioprinting and on-demand biofabrication of human organs and tissues. Last year the company reflected that evolution by changing its name from CELLINK Life Sciences to BICO, short for “bioconvergence”—a combination of biology, engineering and computer science technologies for healthcare and life-sci applications that include robotics, artificial intelligence, advanced genomics and bioprinting . . .
